EriVan Bio specializes in the production and research of exosomes derived from various biological sources, including adipose-derived mesenchymal stem cells, bovine milk, and human plasma. Their offerings include exosomes from umbilical cord and bone marrow sources, as well as from a range of other cell lines and tissues. These exosomes are intended for research purposes and are processed to ensure they are free from major human viruses, making them suitable for various applications in the biopharmaceutical industry. EriVan Bio emphasizes the importance of exosomes in advancing research, particularly in the context of their therapeutic potential.

The company highlights the role of exosomes in neuroscience, particularly their ability to facilitate communication within the nervous system and their involvement in neurological disorders. Exosomes are recognized for their capacity to cross the blood-brain barrier, which is a significant challenge in drug delivery for neurodegenerative diseases. EriVan Bio's research suggests that exosomes derived from stem cells may possess anti-neuroinflammatory properties and promote neurogenesis, offering promising avenues for treating conditions such as Alzheimer's, Parkinson's, and traumatic brain injuries. This innovative approach positions exosomes as a critical component in the development of new therapeutic strategies for complex neurological conditions.

United States

EriVan Bio is a biotechnology company that focuses on innovating and delivering products and services related to exosome technology for molecular and cell biology research, regenerative medicine, and drug delivery.

EriVan Bio

Company Details